Remed Co.Ltd Cash Flow Conversion Efficiency
Remed Co.Ltd cash flow conversion efficiency. Based on the latest financial reports, Remed Co.Ltd (302550) has a cash flow conversion efficiency ratio of 0.047x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.74 Billion ≈ $1.18 Million USD) by net assets (₩37.17 Billion ≈ $25.19 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Remed Co.Ltd (2017–2025)
Cash flow conversion efficiency of Remed Co.Ltd from 2017 to 2025. This chart illustrates how Remed Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Remed Co.Ltd share price for real-time trading data and today's change.
Remed Co.Ltd Cash Flow Conversion Ratio Explained
Remed Co.Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Remed Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Remed Co.Ltd ranked by their cash flow conversion efficiency. Also see how much is Remed Co.Ltd worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bluebird bio Inc
NASDAQ:BLUE
|
0.751x |
|
Quartiers Properties AB
ST:QUART
|
0.048x |
|
Riverview Rubber Estates Bhd
KLSE:2542
|
0.009x |
|
Abrdn PLC
LSE:ABDN
|
0.044x |
|
Roundtop Machinery Industries Co Ltd
TW:1540
|
0.039x |
|
Everbrite Technology Co Ltd
TWO:4523
|
-0.042x |
|
Hancom WITH Inc
KQ:054920
|
-0.060x |
|
Peninsula Land Limited
NSE:PENINLAND
|
0.090x |
Annual Cash Flow Conversion Efficiency for Remed Co.Ltd (2017–2025)
The table below shows the annual cash flow conversion efficiency of Remed Co.Ltd from 2017 to 2025. Review Remed Co.Ltd (302550) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩39.46 Billion ≈ $26.74 Million |
₩2.40 Billion ≈ $1.62 Million |
0.061x | +96.37% |
| 2024-12-31 | ₩40.25 Billion ≈ $27.28 Million |
₩1.24 Billion ≈ $843.40K |
0.031x | -72.79% |
| 2023-12-31 | ₩30.79 Billion ≈ $20.87 Million |
₩3.50 Billion ≈ $2.37 Million |
0.114x | -34.77% |
| 2022-12-31 | ₩29.92 Billion ≈ $20.28 Million |
₩5.21 Billion ≈ $3.53 Million |
0.174x | +230.28% |
| 2021-12-31 | ₩26.10 Billion ≈ $17.69 Million |
₩-3.49 Billion ≈ $-2.36 Million |
-0.134x | -227.93% |
| 2020-12-31 | ₩24.79 Billion ≈ $16.80 Million |
₩2.59 Billion ≈ $1.76 Million |
0.105x | -20.14% |
| 2019-12-31 | ₩24.62 Billion ≈ $16.69 Million |
₩3.22 Billion ≈ $2.18 Million |
0.131x | +550.48% |
| 2018-12-31 | ₩10.94 Billion ≈ $7.42 Million |
₩-317.96 Million ≈ $-215.48K |
-0.029x | -282.16% |
| 2017-12-31 | ₩4.19 Billion ≈ $2.84 Million |
₩66.75 Million ≈ $45.24K |
0.016x | -- |
About Remed Co.Ltd
Remed Co.,Ltd. engages in the manufacture and supply of medical devices worldwide. The company offers transcranial magnetic stimulator, a technology for the treatment of disorders, such as stroke, autism, dementia, Parkinson's disease, developmental disorders, and tinnitus. It also offers neuro magnetic stimulation systems for helping blood circulation, treating pain, neurons, regenerating cells,… Read more